Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Triaminic Vapor Patch Adverse Events Prompt Recall By Novartis

This article was originally published in The Tan Sheet

Executive Summary

Eight complaints of adverse health effects resulting from accidental ingestion of the Triaminic Vapor Patch have prompted a nationwide recall of products in the line by Novartis Consumer Healthcare

You may also be interested in...



Environmental Group Opposes FDA Adding Triclosan To OTC Monographs

Environmental regulations could impede a group's attempt to block all non-medical uses of triclosan - including in OTC products

Environmental Group Opposes FDA Adding Triclosan To OTC Monographs

Environmental regulations could impede a group's attempt to block all non-medical uses of triclosan - including in OTC products

WellPatch Vapor Pads recalled

FDA and Metholatum have issued a voluntary recall for WellPatch Cough & Cold Soothing Vapor Pads due to the possibility of pediatric ingestion. The topical cough suppressant label indicates the product is suitable for children 2 years and older. The placement of the products on the chest gives young children easy access to remove the patches from their chests and possibly ingest them. Adverse events associated with menthol ingestion range from minor symptoms to seizures, an FDA MedWatch release notes. No serious adverse events linked to the WellPatch product have been reported to date. Triaminic Vapor Patches were similarly recalled in June 2006 due to reported adverse events related to pediatric ingestion (1"The Tan Sheet" June 26, 2006, p. 8)...

Related Content

Topics

UsernamePublicRestriction

Register

ID036688

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel